

In the Claims:

Amendments to the Claims:

The following amended Claim listing replaces all prior versions of the Claims in the application.

- 1-9. (Canceled)
10. (Previously Presented) A composition for the inhibition of restenosis comprising an ADP receptor antagonist and a thromboxane A₂ receptor antagonist.
11. (Previously Presented) The composition of Claim 10, wherein the ADP receptor antagonist is selected from the group consisting of ticlopidine and clopidogrel.
12. (Previously Presented) The composition of Claim 10, wherein the ADP receptor antagonist comprises clopidogrel.
13. (Previously Presented) The composition of Claim 10, wherein the thromboxane A₂ receptor antagonist comprises ridogrel.
14. (Previously Presented) The composition of Claim 10, wherein the ADP receptor antagonist and the thromboxane A₂ receptor antagonist are each in solution in a physiologic liquid carrier at a concentration of no greater than 100,000 nanomolar.
15. (Previously Presented) The composition of Claim 10, wherein the ADP receptor antagonist and the thromboxane A₂ receptor antagonist are each in solution in a physiologic liquid carrier at a concentration of no greater than 10,000 nanomolar.
- 16-24. (Canceled)
25. (Previously Presented) A cardiovascular therapeutic composition comprising an ADP receptor antagonist and a thromboxane A₂ receptor antagonist.
26. (Previously Presented) A pharmaceutical combination comprising an ADP receptor blocking antiplatelet drug and a thromboxane A₂ receptor antagonist.
27. (Previously Presented) The composition of Claim 26, wherein the ADP receptor blocking antiplatelet drug comprises clopidogrel.
28. (Canceled)